WuXi Biologics has launched EffiX™, a new microbial expression platform designed to improve the production of recombinant proteins and plasmid DNA.
The EffiX™ platform is a proprietary microbial expression system developed by WuXi Biologics to enhance the production of recombinant proteins and plasmid DNA (pDNA). Built on an optimised E. coli system, EffiX™ is designed to achieve high yield, stability, and scalability, addressing key challenges in microbial-based biologics manufacturing.
The platform is based on a proprietary E. coli system engineered for high yield, stability, and scalability.
The demand for microbial-derived products is growing, particularly for antibody fragments, nanobodies, enzymes, cytokines, antigens, polypeptides, and plasmid DNA (pDNA). These biomolecules play a critical role in next-generation therapies, but their production presents challenges.
The EffiX™ platform aims to address these issues by offering high productivity, consistent quality, and reliable scalability. It achieves titers exceeding 15 g/L for non-monoclonal antibody recombinant proteins and over 1 g/L for plasmid DNA.
By integrating advanced microbial solutions, WuXi Biologics continues to enhance its capabilities, aiming to accelerate the development of high-quality and accessible biologics for global healthcare needs.
